Notably, elevated PDE4C expression is strongly associated with lower survival and poorer treatment outcomes in a variety of malignant tumors, such as myelodysplastic syndromes (MDS), pancreatic cancer, and lung cancer (55, 85, 86). This evidence concerns the gene PDE4C and myelodysplastic syndrome.